Novus Therapeutics Inc., of Irvine, Calif., said it elected to postpone its public offering due to market conditions, including valuation sensitivity at the current share price. As of June 30, the company, which develops products for ear, nose and throat disorders, had about $19.2 million in cash and equivalents.